Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Abdullatif Al Khedr, Nolan Campbell et al.|The Lancet Neurology|2018

Cited by 345